세계의 반성 부비동염 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 질환 표현형별, 치료 유형별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Chronic Rhinosinusitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Phenotype, By Treatment Type, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,356,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,768,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,300,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

반성 부비동염 세계 시장 규모는 2024년 26억 2,000만 달러로 평가되었습니다. 예측 기간 동안 39억 9,000만 달러에 달하고, 2030년까지 7.23%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

세계 반성 부비동염 시장은 반성 부비동염(CRS)은 코와 부비동에 영향을 미치는 만성 염증성 질환으로 코 막힘, 안면 통증, 후각 장애 등의 증상을 유발하는 만성 염증성 질환으로, 반성 부비동염(CRS)은 유행성, 지속성 질환으로 역동적으로 진화하는 헬스케어 분야입니다. 이 시장에는 증상 완화, 염증 감소, 환자의 전반적인 삶의 질 향상을 목표로 하는 다양한 의약품, 의료기기, 치료방법이 포함되어 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	26억 2,000만 달러
시장 규모 : 2030년	39억 9,000만 달러
CAGR : 2025-2030년	7.23%
급성장 부문	호산구성 만성 부비동염
최대 시장	북미

반성 부비동염 세계 시장의 성장 촉진요인 중 하나는 전 세계 CRS 발병률 증가입니다. 환경오염물질, 알레르기, 생활습관 변화 등의 요인이 CRS의 유병률 증가에 기여하고 있으며, 효과적인 치료법을 찾는 환자들이 증가하고 있습니다. 의료진과 제약사들은 CRS를 관리하고 환자들에게 장기적인 완화를 제공하기 위해 생물학적 제제, 부신피질 스테로이드, 항생제 등 혁신적인 치료법을 도입하기 위한 연구개발에 적극 나서고 있습니다.

시장 성장 촉진요인

반성 부비동염의 유병률 상승

주요 시장 이슈

높은 치료비

주요 시장 동향

생물학적 치료

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 반성 부비동염 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 질환 표현형별(비호산구성 만성 부비동염, 호산구성 만성 부비동염, 감염성 만성 부비동염, 알레르기성 진균성 부비강염, 기타)
  • 치료 유형별(의료기기, 의약품, 점비약, 스테로이드 점비약, 수술, 기타)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 질환 표현 형 별
  • 치료 유형별
  • 유통 채널별
  • 지역별

제5장 아시아태평양의 반성 부비동염 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 질환 표현 형 별
  • 치료 유형별
  • 유통 채널별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 반성 부비동염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 반성 부비동염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 반성 부비동염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 반성 부비동염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 반성 부비동염 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Lyra Therapeutics
• Novartis AG
• Medtronic plc
• GlaxoSmithKline plc
• AstraZeneca Plc
• Sanofi AG
• Dr. Reddy's Laboratories Ltd.
• Stryker Corporation
• Bayer AG
• Smith & Nephew Plc

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Chronic Rhinosinusitis Market was valued at USD 2.62 Billion in 2024 and is expected to reach USD 3.99 Billion in the forecast period with a CAGR of 7.23% through 2030. The Global Chronic Rhinosinusitis Market is a dynamic and evolving healthcare sector dedicated to addressing the prevalent and persistent condition of chronic rhinosinusitis (CRS). CRS is a chronic inflammatory disease affecting the nasal and sinus passages, leading to symptoms such as nasal congestion, facial pain, and impaired sense of smell. This market encompasses a wide range of pharmaceuticals, medical devices, and treatment modalities aimed at alleviating symptoms, reducing inflammation, and improving the overall quality of life for affected individuals.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.62 Billion
Market Size 2030	USD 3.99 Billion
CAGR 2025-2030	7.23%
Fastest Growing Segment	Eosinophilic Chronic Rhinosinusitis
Largest Market	North America

One of the primary drivers of growth in the Global Chronic Rhinosinusitis Market is the increasing incidence of CRS worldwide. Factors such as environmental pollutants, allergies, and lifestyle changes contribute to the rising prevalence of this condition, creating a substantial patient pool seeking effective treatments. Healthcare providers and pharmaceutical companies are actively engaged in research and development efforts to introduce innovative therapies, including biologics, corticosteroids, and antibiotics, to manage CRS and provide long-term relief to patients.

Key Market Drivers

Rising Prevalence of Chronic Rhinosinusitis

Chronic Rhinosinusitis (CRS), characterized by prolonged inflammation of the nasal and sinus passages, has seen a notable increase in prevalence globally, significantly impacting the healthcare landscape. This rise is attributed to various factors, including environmental pollution, lifestyle changes, and heightened awareness leading to more frequent diagnoses.

Environmental pollution plays a substantial role in the escalating incidence of CRS. Exposure to air pollutants, particularly particulate matter (PM), has been correlated with increased CRS prevalence and severity. Studies indicate that for each unit increase in PM2.5, there is a 1.89-fold increased risk in the proportion of CRS patients requiring sinus surgery. Additionally, research has shown that long-term exposure to PM2.5 is associated with the development of CRS, underscoring the impact of environmental factors on this condition.

Key Market Challenges

High Treatment Costs

High treatment costs stand out as a significant hindrance in the Global Chronic Rhinosinusitis (CRS) Market, impacting both patients and healthcare systems alike. Chronic Rhinosinusitis, a persistent inflammatory condition of the nasal and sinus passages, requires comprehensive treatment approaches, including diagnostic tests, pharmaceuticals, surgical interventions, and long-term management. The cost associated with these aspects of care can present substantial challenges. One of the primary concerns related to high treatment costs is the financial burden it places on patients. Diagnostic procedures such as computed tomography (CT) scans and magnetic resonance imaging (MRI) can be expensive, and these costs are often not fully covered by insurance plans.

Key Market Trends

Biologic Therapies

Biologic therapies have emerged as a powerful and transformative force in boosting the Global Chronic Rhinosinusitis (CRS) Market. Chronic Rhinosinusitis, characterized by persistent inflammation of the nasal and sinus passages, has historically presented a challenging treatment landscape. However, biologic therapies, including monoclonal antibodies and other targeted drugs, have revolutionized the management of CRS and are driving significant growth in the market.

One of the key factors contributing to the success of biologic therapies is their precision in addressing the underlying inflammatory pathways and immune responses that drive CRS. These therapies are designed to specifically target and inhibit molecules or receptors involved in the inflammatory cascade, thereby reducing symptoms and improving the quality of life for CRS patients. By directly tackling the root causes of inflammation, biologics offer a highly effective and targeted approach to treatment.

Key Market Players

Lyra Therapeutics

Novartis AG

Medtronic plc

GlaxoSmithKline plc

AstraZeneca Plc

Sanofi AG

Dr. Reddy's Laboratories Ltd.

Stryker Corporation

Bayer AG

Smith & Nephew Plc

Report Scope:

In this report, the Global Chronic Rhinosinusitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Rhinosinusitis Market, By Disease Phenotype:

• Non-Eosinophilic Chronic Rhinosinusitis
• Eosinophilic Chronic Rhinosinusitis
• Infectious Chronic Rhinosinusitis
• Allergic Fungal Rhinosinusitis
• Others

Chronic Rhinosinusitis Market, By Treatment Type

• Medical Devices
• Drugs
• Nasal Drops
• Steroid Nasal Sprays
• Surgery
• Others

Chronic Rhinosinusitis Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Chronic Rhinosinusitis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Rhinosinusitis Market.

Available Customizations:

Global Chronic Rhinosinusitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Chronic Rhinosinusitis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Disease Phenotype (Non-Eosinophilic Chronic Rhinosinusitis, Eosinophilic Chronic Rhinosinusitis, Infectious Chronic Rhinosinusitis, Allergic Fungal Rhinosinusitis, Others)
  • 4.2.2. By Treatment Type (Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Disease Phenotype
  • 4.3.2. By Treatment Type
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Chronic Rhinosinusitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Phenotype
  • 5.2.2. By Treatment Type
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Chronic Rhinosinusitis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Disease Phenotype
      • 5.3.1.2.2. By Treatment Type
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Chronic Rhinosinusitis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Disease Phenotype
      • 5.3.2.2.2. By Treatment Type
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Chronic Rhinosinusitis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Disease Phenotype
      • 5.3.3.2.2. By Treatment Type
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Chronic Rhinosinusitis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Disease Phenotype
      • 5.3.4.2.2. By Treatment Type
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Chronic Rhinosinusitis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Disease Phenotype
      • 5.3.5.2.2. By Treatment Type
      • 5.3.5.2.3. By Distribution Channel

6. Europe Chronic Rhinosinusitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Phenotype
  • 6.2.2. By Treatment Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Chronic Rhinosinusitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Phenotype
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Chronic Rhinosinusitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Phenotype
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Chronic Rhinosinusitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Phenotype
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Chronic Rhinosinusitis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease Phenotype
      • 6.3.4.2.2. By Treatment Type
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Chronic Rhinosinusitis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease Phenotype
      • 6.3.5.2.2. By Treatment Type
      • 6.3.5.2.3. By Distribution Channel

7. North America Chronic Rhinosinusitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Phenotype
  • 7.2.2. By Treatment Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Chronic Rhinosinusitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Phenotype
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Chronic Rhinosinusitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Phenotype
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Chronic Rhinosinusitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Phenotype
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Distribution Channel

8. South America Chronic Rhinosinusitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Phenotype
  • 8.2.2. By Treatment Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Chronic Rhinosinusitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Phenotype
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Chronic Rhinosinusitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Phenotype
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Chronic Rhinosinusitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Phenotype
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Chronic Rhinosinusitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Phenotype
  • 9.2.2. By Treatment Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Chronic Rhinosinusitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Phenotype
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Chronic Rhinosinusitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Phenotype
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Chronic Rhinosinusitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Phenotype
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Chronic Rhinosinusitis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Lyra Therapeutics
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Medtronic plc
• 14.4. GlaxoSmithKline plc
• 14.5. AstraZeneca Plc
• 14.6. Sanofi AG
• 14.7. Dr. Reddy's Laboratories Ltd.
• 14.8. Stryker Corporation
• 14.9. Bayer AG
• 14.10.Smith & Nephew Plc

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료